United States Eventing Association

Adequan Returns as the Official Joint Therapy Treatment of the USEA

The United States Eventing Association (USEA) would like to welcome back longtime sponsor Adequan^® i.m. (polysulfated glycosaminoglycan) as “The Official Joint Therapy Treatment of the USEA”, Title Sponsor of the USEA Gold Cup Series and Contributing Level Sponsor of the USEA American Eventing Championships (AEC). Now in its 14^th year, the Gold Cup Series consists of 11 qualifying competitions at the Advanced and CIC3* levels which will culminate at the 2018 USEA American Eventing Championships, August 29-September 2, 2018, at the Colorado Horse Park in Parker, Colorado. The $40,000 Adequan USEA Gold Cup Advanced division serves as the Gold Cup Final at the AEC and the winner of the division will be named the 2018 Adequan USEA Gold Cup Champion.

“Our partnership with the USEA since 2005 continues to be one of our core relationships,” states Allyn Mann, Director of Strategic Partnerships at Luitpold Animal Health. “The Adequan Gold Cup Series and Championship is an important component of our sponsorship. The sport of eventing requires so much and this is one way we can give back to this wonderful community.”

“Year in and year out Adequan steps up to support the sport of eventing in the U.S.,” said USEA CEO Rob Burk. “We are very thankful to be partnered with the company that produces the only product approved by the FDA for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. Eventers care about the health and wellbeing of our equine partners which is why many of our top horses are active in the sport well into their later years.”

About Adequan^® i.m. (polysulfated glycosaminoglycan)

Adequan® i.m. is indicated for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses. Luitpold Pharmaceuticals, manufacturer of Adequan® invites you to learn more about their products by visiting their website.

About the United States Eventing Association

The USEA is a non-profit 501 C (3), educational organization committed to providing eventing enthusiasts with a competitive level suited to their individual skills. By assisting and educating competitors, event organizers and officials; maintaining responsible safety standards; and registering qualified competitions and clinics, the USEA offers a strong and continuous training opportunity for an ever-expanding field of world-class competitors. Just as importantly, the USEA provides a means for all riders, regardless of age or ability, to experience the thrill of eventing. Learn more about the USEA by visiting the website.

Adequan® i.m.

Brand of Polysulfated Glycosaminoglycan (PSGAG)

INDICATIONS

Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

IMPORTANT SAFETY INFORMATION

There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Iss 3/2018

PP-AI-US-0103